Role of Acid Sphingomyelinase in Shifting the Balance Between Proinflammatory and Reparative Bone Marrow Cells in Diabetic Retinopathy

Harshini Chakravarthy, Svetlana Navitskaya, Sandra O'Reilly, Jacob Gallimore, Hannah Mize, Eleni Beli, Qi Wang, Nermin Kady, Chao Huang, Gary J. Blanchard, Maria B. Grant, Julia V. Busik

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The metabolic insults associated with diabetes lead to low-grade chronic inflammation, retinal endothelial cell damage, and inadequate vascular repair. This is partly due to the increased activation of bone marrow (BM)-derived proinflammatory monocytes infiltrating the retina, and the compromised function of BM-derived reparative circulating angiogenic cells (CACs), which home to sites of endothelial injury and foster vascular repair. We now propose that a metabolic link leading to activated monocytes and dysfunctional CACs in diabetes involves upregulation of a central enzyme of sphingolipid signaling, acid sphingomyelinase (ASM). Selective inhibition of ASM in the BM prevented diabetes-induced activation of BM-derived microglia-like cells and normalized proinflammatory cytokine levels in the retina. ASM upregulation in diabetic CACs caused accumulation of ceramide on their cell membrane, thereby reducing membrane fluidity and impairing CAC migration. Replacing sphingomyelin with ceramide in synthetic membrane vesicles caused a similar decrease in membrane fluidity. Inhibition of ASM in diabetic CACs improved membrane fluidity and homing of these cells to damaged retinal vessels. Collectively, these findings indicate that selective modulation of sphingolipid metabolism in BM-derived cell populations in diabetes normalizes the reparative/proinflammatory cell balance and can be explored as a novel therapeutic strategy for treating diabetic retinopathy.

Original languageEnglish (US)
JournalStem Cells
DOIs
StateAccepted/In press - 2016

Fingerprint

Sphingomyelin Phosphodiesterase
Diabetic Retinopathy
Bone Marrow Cells
Membrane Fluidity
Acids
Bone Marrow
Sphingolipids
Ceramides
Retina
Monocytes
Up-Regulation
Cell Membrane
Retinal Vessels
Sphingomyelins
Vascular System Injuries
Microglia
Cell Movement
Blood Vessels
Endothelial Cells
Cytokines

Keywords

  • Bone marrow transplantation
  • Diabetic retinopathy
  • Dyslipidemias
  • Sphingolipids
  • Vascular system injuries

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Chakravarthy, H., Navitskaya, S., O'Reilly, S., Gallimore, J., Mize, H., Beli, E., ... Busik, J. V. (Accepted/In press). Role of Acid Sphingomyelinase in Shifting the Balance Between Proinflammatory and Reparative Bone Marrow Cells in Diabetic Retinopathy. Stem Cells. https://doi.org/10.1002/stem.2259

Role of Acid Sphingomyelinase in Shifting the Balance Between Proinflammatory and Reparative Bone Marrow Cells in Diabetic Retinopathy. / Chakravarthy, Harshini; Navitskaya, Svetlana; O'Reilly, Sandra; Gallimore, Jacob; Mize, Hannah; Beli, Eleni; Wang, Qi; Kady, Nermin; Huang, Chao; Blanchard, Gary J.; Grant, Maria B.; Busik, Julia V.

In: Stem Cells, 2016.

Research output: Contribution to journalArticle

Chakravarthy, H, Navitskaya, S, O'Reilly, S, Gallimore, J, Mize, H, Beli, E, Wang, Q, Kady, N, Huang, C, Blanchard, GJ, Grant, MB & Busik, JV 2016, 'Role of Acid Sphingomyelinase in Shifting the Balance Between Proinflammatory and Reparative Bone Marrow Cells in Diabetic Retinopathy', Stem Cells. https://doi.org/10.1002/stem.2259
Chakravarthy, Harshini ; Navitskaya, Svetlana ; O'Reilly, Sandra ; Gallimore, Jacob ; Mize, Hannah ; Beli, Eleni ; Wang, Qi ; Kady, Nermin ; Huang, Chao ; Blanchard, Gary J. ; Grant, Maria B. ; Busik, Julia V. / Role of Acid Sphingomyelinase in Shifting the Balance Between Proinflammatory and Reparative Bone Marrow Cells in Diabetic Retinopathy. In: Stem Cells. 2016.
@article{e0c90f578f5c42d4856f4d86336a7d5c,
title = "Role of Acid Sphingomyelinase in Shifting the Balance Between Proinflammatory and Reparative Bone Marrow Cells in Diabetic Retinopathy",
abstract = "The metabolic insults associated with diabetes lead to low-grade chronic inflammation, retinal endothelial cell damage, and inadequate vascular repair. This is partly due to the increased activation of bone marrow (BM)-derived proinflammatory monocytes infiltrating the retina, and the compromised function of BM-derived reparative circulating angiogenic cells (CACs), which home to sites of endothelial injury and foster vascular repair. We now propose that a metabolic link leading to activated monocytes and dysfunctional CACs in diabetes involves upregulation of a central enzyme of sphingolipid signaling, acid sphingomyelinase (ASM). Selective inhibition of ASM in the BM prevented diabetes-induced activation of BM-derived microglia-like cells and normalized proinflammatory cytokine levels in the retina. ASM upregulation in diabetic CACs caused accumulation of ceramide on their cell membrane, thereby reducing membrane fluidity and impairing CAC migration. Replacing sphingomyelin with ceramide in synthetic membrane vesicles caused a similar decrease in membrane fluidity. Inhibition of ASM in diabetic CACs improved membrane fluidity and homing of these cells to damaged retinal vessels. Collectively, these findings indicate that selective modulation of sphingolipid metabolism in BM-derived cell populations in diabetes normalizes the reparative/proinflammatory cell balance and can be explored as a novel therapeutic strategy for treating diabetic retinopathy.",
keywords = "Bone marrow transplantation, Diabetic retinopathy, Dyslipidemias, Sphingolipids, Vascular system injuries",
author = "Harshini Chakravarthy and Svetlana Navitskaya and Sandra O'Reilly and Jacob Gallimore and Hannah Mize and Eleni Beli and Qi Wang and Nermin Kady and Chao Huang and Blanchard, {Gary J.} and Grant, {Maria B.} and Busik, {Julia V.}",
year = "2016",
doi = "10.1002/stem.2259",
language = "English (US)",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Role of Acid Sphingomyelinase in Shifting the Balance Between Proinflammatory and Reparative Bone Marrow Cells in Diabetic Retinopathy

AU - Chakravarthy, Harshini

AU - Navitskaya, Svetlana

AU - O'Reilly, Sandra

AU - Gallimore, Jacob

AU - Mize, Hannah

AU - Beli, Eleni

AU - Wang, Qi

AU - Kady, Nermin

AU - Huang, Chao

AU - Blanchard, Gary J.

AU - Grant, Maria B.

AU - Busik, Julia V.

PY - 2016

Y1 - 2016

N2 - The metabolic insults associated with diabetes lead to low-grade chronic inflammation, retinal endothelial cell damage, and inadequate vascular repair. This is partly due to the increased activation of bone marrow (BM)-derived proinflammatory monocytes infiltrating the retina, and the compromised function of BM-derived reparative circulating angiogenic cells (CACs), which home to sites of endothelial injury and foster vascular repair. We now propose that a metabolic link leading to activated monocytes and dysfunctional CACs in diabetes involves upregulation of a central enzyme of sphingolipid signaling, acid sphingomyelinase (ASM). Selective inhibition of ASM in the BM prevented diabetes-induced activation of BM-derived microglia-like cells and normalized proinflammatory cytokine levels in the retina. ASM upregulation in diabetic CACs caused accumulation of ceramide on their cell membrane, thereby reducing membrane fluidity and impairing CAC migration. Replacing sphingomyelin with ceramide in synthetic membrane vesicles caused a similar decrease in membrane fluidity. Inhibition of ASM in diabetic CACs improved membrane fluidity and homing of these cells to damaged retinal vessels. Collectively, these findings indicate that selective modulation of sphingolipid metabolism in BM-derived cell populations in diabetes normalizes the reparative/proinflammatory cell balance and can be explored as a novel therapeutic strategy for treating diabetic retinopathy.

AB - The metabolic insults associated with diabetes lead to low-grade chronic inflammation, retinal endothelial cell damage, and inadequate vascular repair. This is partly due to the increased activation of bone marrow (BM)-derived proinflammatory monocytes infiltrating the retina, and the compromised function of BM-derived reparative circulating angiogenic cells (CACs), which home to sites of endothelial injury and foster vascular repair. We now propose that a metabolic link leading to activated monocytes and dysfunctional CACs in diabetes involves upregulation of a central enzyme of sphingolipid signaling, acid sphingomyelinase (ASM). Selective inhibition of ASM in the BM prevented diabetes-induced activation of BM-derived microglia-like cells and normalized proinflammatory cytokine levels in the retina. ASM upregulation in diabetic CACs caused accumulation of ceramide on their cell membrane, thereby reducing membrane fluidity and impairing CAC migration. Replacing sphingomyelin with ceramide in synthetic membrane vesicles caused a similar decrease in membrane fluidity. Inhibition of ASM in diabetic CACs improved membrane fluidity and homing of these cells to damaged retinal vessels. Collectively, these findings indicate that selective modulation of sphingolipid metabolism in BM-derived cell populations in diabetes normalizes the reparative/proinflammatory cell balance and can be explored as a novel therapeutic strategy for treating diabetic retinopathy.

KW - Bone marrow transplantation

KW - Diabetic retinopathy

KW - Dyslipidemias

KW - Sphingolipids

KW - Vascular system injuries

UR - http://www.scopus.com/inward/record.url?scp=84953242795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953242795&partnerID=8YFLogxK

U2 - 10.1002/stem.2259

DO - 10.1002/stem.2259

M3 - Article

C2 - 26676316

AN - SCOPUS:84953242795

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

ER -